You searched for "DMO"
Retinitis pigmentosa (RP) associated cystoid macular oedema (CMO)
This is a review article from two units in the UK and Australia, highlighting the supporting evidence of possible pathogenesis and treatment modalities of CMO in RP. The authors proposed that the likely mechanisms for RP-CMO involved the breakdown of...Management of retinal diseases: highlights from the AAO 2019 Retina Subspecialty Day Meeting
The author highlights current debate, opinion and late breaking developments in the management of retinal diseases. The American Academy of Ophthalmology’s 2019 Retina Subspecialty Day Meeting was held on 11-12 October, 2019 in San Francisco, USA. Established and emerging innovative...100% Optical and Optrafair organisers join forces
From now on there will be one major annual exhibition, 100% Optical at London’s ExCeL exhibition centre, which has full industry support from the FMO and other major optical bodies.NICE drugs: an update on what’s good to go
Treatment options recommended by the National Institute for Health and Care Excellence (NICE) must be readily available for use in the NHS of England and Wales. This article provides an overview of recent guidance from NICE and summary advice issued...Belfast briefing: Retina Day roundup from the RCOphth 2024 Annual Congress
Belfast hosted this year’s Royal College of Ophthalmologists’ (RCOphth) Annual Congress, a meeting dedicated to sharing advances, knowledge and clinical practice points in ophthalmic care. This article summarises selected talks by medical and surgical retina specialists during the Retina Subspecialty...
Does intravitreal bevacizumab help in diabetic retinopathy related vitreous haemorrhage?
This retrospective, interventional case series, aimed to assess the effectiveness of intravitreal bevacizumab (IVB) in vitreous haemorrhage secondary to proliferative diabetic retinopathy. The primary outcome was the rate of vitrectomy (PPV) after IVB, with secondary outcomes the number of IVB...
Lucentis for pseudophakic CMO
Pseudophakic cystoid macular oedema (CMO) develops angiographically in up to 20-30% after uneventful phacoemulsification. This study aimed to evaluate the potential efficacy and safety of intravitreal ranibizumab in patients with pseudophakic CMO after cataract surgery. Seven eyes were included in...All eyes on Twiggy as she fronts new campaign warning us: don’t lose focus of your eye health
Dame Twiggy Lawson fronts a new public awareness campaign focused on eye health, as cases of macular disease increase with our ageing population.
RaScaL Study
The RaScaL study was a six month, single-centre, controlled, prospective phase I/II study in which subjects with diabetic macular oedema (DME) and associated peripheral nonperfusion on ultrawide-field fluorescein angiography (UWFA) were randomised to: (1) study arm: ranibizumab (0.5 mg) injection...
Patients’ perspective over quality of care and cataract surgery
This study analyses the factors of perceived quality of care among patients undergoing cataract surgery. A questionnaire was designed to assess the patients’ views about the quality of care using QUOTE (Quality of Care through the Patient’s Eyes), which assessed...
